- Details
- In this Society of Nuclear Medicine and Molecular Imaging (SNMMI) webinar Michael Gorin and Frankis Almaguel present on PSMA-targeted PET imaging of prostate cancer. Dr. Gorin kicks off the webinar by talking about the basics of PSMA targeted imaging, what the target is, where the need for molecular imaging testing in prostate cancer comes from, what led to their approval, and what agents are avai...
|
- Details
- Phillip Koo is joined by Hossein Jadvar to discuss the Appropriate Use Criteria (AUC) for PSMA PET in prostate cancer. Dr. Jadvar, the first author of the publication, discusses the process of developing the AUC for PSMA PET in prostate cancer and reviews 11 clinical scenarios that may be encountered by ordering professionals when they want to consult the AUC for ordering their imaging. To guide r...
|
- Details
- In this educational video presentation from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Drs Neha Maithel and Isis Gayed present on imaging in prostate cancer with a focus on F-18 Axumin® PET. Axumin (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific a...
|
- Details
- In this Society of Nuclear Medicine and Molecular Imaging (SNMMI), Satellite Symposium entitled PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know Michael Gorin, MD presents on PSMA-targeted PET Imaging of Prostate Cancer - A Primer for Urologists. Dr. Gorin starts with reviewing conventional imaging modalities for prostate cancer which have proved insufficient for detectin...
|
- Details
- Following presentations from Micheal Gorin and Steven Rowe during this Society of Nuclear Medicine and Molecular Imaging (SNMMI) Satellite Symposium entitled PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know presented in conjunction with the American Urological Association Annual Meeting, the pair engage in a question and answer session. Drs. Gorin and Rowe comment on thei...
|
- Details
- In this Society of Nuclear Medicine and Molecular Imaging (SNMMI) Satellite Symposium entitled PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know Steven Rowe, MD presents on PSMA-Targeted PET Imaging: Metastatic Disease, Response Assessment, Future Directions, and Read Paradigms. In his talk, he focuses on PSMA PET imaging in the context of metastatic disease, both small vo...
|
- Details
- As part of this patient-centered video series of lectures on prostate cancer diagnosis and treatment, Dr Sethi presents the timing for radium-223 treatment in mCRPC. She details who qualifies as a candidate for radium 223 therapy, how it is given, the limited side effects of this treatment, that PSA is not a biomarker for treatment success and other treatment management considerations. Biography:...
|
- Details
- Bennett Chin discusses Lutetium-177 PSMA, an investigational class of targeted, radionuclide agents. The focus of this treatment is on Prostate-Specific Membrane Antigen (PSMA), a molecule overexpressed on higher-grade prostate cancer cells. Lutetium-177 is a radioactive beta emitter that binds to PSMA, delivering highly targeted radiation therapy to prostate cancer cells. This emitter also has mi...
|
- Details
- In this educational video from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Dr Bital Savir-Baruch, a nuclear medicine physician from Loyola University Medical Center, covers the limitation of conventional imaging for localized prostate cancer sites in patients with suspected disease recurrence, and the role of fluciclovine PET CT imaging in prostate cancer recurrence. Biographies...
|
- Details
- In this lecture, Richard Baum presents the development and practices of the Theranostic Imaging Center in Bad Berka, Germany where he focuses on the use of screening methods to promote "precision oncology". He highlights the use of prostate-specific membrane antigen (PSMA) for prostate cancer. Imaging for PSMA allows doctors to properly assign patients to therapy responses using predictive measure...
|
